Bayer AG Moves to Phase 2 Clinical Trial for New Gene Therapy for Parkinson Disease

Recently, Bayer AG, a German multinational pharmaceutical and biotechnology company, reported that its gene therapy  early-stage trials for Parkinson disease were successful so far. In 2024, the company plans to move into a phase II study. The phase II study will focus on the short-term impacts of treatment and further evaluate its effectiveness with Parkinson disease.

In a recent statement, Bayer AG confirmed that the gene therapy had no serious adverse events when tested among its 11 patients in the first trial. Researchers tested gene therapy over the course of 18 months and patients effects were well-tolerated.

In the summer of 2023, Bayer AG also announced they were working on a stem cell therapy for patients with Parkinson disease. And over the past decade, Bayer AG acquired the 2 therapies through its deals with companies such as Asklepios BioPharmaceutical Inc. and BlueRock Therapeutics. BlueRock Therapeutics’  phase 1 bemdaneprocel trial and Bayer AG’s gene therapy trials could revolutionize the future of care for patients with Parkinson disease.